HRMYHarmony Biosciences Holdings, Inc.
Pharmaceutical Preparations
- Revenue
- $868M
- 22% YoY
- Operating margin
- 24.0%
- 10% YoY
- EBITDA
- $208M
- 9.1% YoY
- Market cap
- —
- Employees
- —
- Net debt / EBITDA
- -1.9×
- −$396M net debt
- AI in 10-K
- —
Red flags 0 of 9
- TSR below peersClear—3+ of last 5 years
- High CEO pay despite TSRClear—Median CEO pay ≥ $15M and TSR flag
- Active 13DClear0 filingsActive-intent 13D in 18 months
- Net insider sellingClear$0 netNet sales over $10M in 12 months
- Earnings not backed by cashClear219% of net incomeCash flow under 80% of net income
- Dilutive SBCClear5% of revenueOver 10% of revenue
- Payouts exceed cash flowClear29% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyClear—Over 40% of assets
- Shareholder dissentClear—Any vote under 80% support
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $305M | $438M | $582M | $715M | $868M | 22% |
| Operating income | $88M | $120M | $192M | $191M | $208M | 9.2% |
| Net income | $35M | $181M | $129M | $145M | $159M | 9.1% |
| Operating cash flow | $99M | $144M | $219M | $220M | $348M | 58% |
| Capex | $298K | $172K | $312K | $1M | $310K | 73% |
| Stock-based comp | $16M | $26M | $32M | $43M | $45M | 5.4% |
| Buybacks | — | — | $100M | — | — |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $3M · 7
- Net
- −$3M
Pay vs performance
No pay-versus-performance disclosure yet.